|Treatment Group||Valgimigli et al. (58)||Ince et al. (56) FIRSTLINE-AMI||Ripa et al. (60) STEMMI||Zohlnhöfer et al. (61) REVIVAL-2||Engelmann et al. (59) G-CSF-STEMI|
|GCSF dosage||5 μg/kg/day for 4 days beginning 37 ± 66 h after symptom onset||10 μg/kg/day for 6 days beginning 85 ± 30 min after reperfusion||10 μg/kg/day for 6 days beginning 1–2 days after AMI||10 μg/kg/day for 5 days beginning 5 days after AMI||10 μg/kg/day for 5 days beginning 6 h to 7 days after symptom onset|
|Duration of follow-up||6 months||4 months||6 months||4–6 months||3 months|
Parameters displaying significantly better performance than was observed in the alternative treatment group are identified with bold italicizedtext. Within-group changes from baseline to follow-up were either insignificant (p > 0.05) or the significance was not reported.
AMI = acute myocardial infarction; GCSF = granulocyte colony-stimulating factor; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; NR = not reported.